FY25 consensus $2.06B. Narrows FY25 adjusted EBITDA view to $140M-$165M from $135M-$165M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target raised to $16 from $14 at Truist
- Evolent Health’s Positive Outlook: Strong Q2 Performance and Promising Pipeline Growth Justify Buy Rating
- Evolent Health appoints Lim as chief clinical officer, Way as CFO
- Evolent Health news Friday ‘incrementally positive,’ says UBS
- GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz